<DOC>
	<DOCNO>NCT00616148</DOCNO>
	<brief_summary>The aim study evaluate ability single oral dose YKP3089 abolish clearly reduce IPS-induced photo-paroxysmal EEG response photosensitive epilepsy patient , measure onset duration effect . Several cohort use , sequentially investigate different dos .</brief_summary>
	<brief_title>Efficacy YKP3089 Patients With Photosensitive Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Male female age 1860 year . A diagnosis history epilepsy patient 02 concomitant antiepileptic drug . If patient take two concomitant medication , second drug must levetiracetam , gabapentin pregabalin . A reproducible IPSinduced photoparoxysmal response ( PPR ) EEG least 3 point frequency assessment scale ( See Section 6.16 ) least one eye condition change 3 frequency 2 repeat measurement record 2 month prior study entry least one eye condition . Patients otherwise good health ( exception epilepsy ) , determine PI via medical history , physical examination screen laboratory investigation . A body mass index ( BMI ) 18 35 . Able willing provide write informed consent participate study accordance ICH , GCP guideline . A history non epileptic seizure ( e.g . metabolic , structural pseudoseizures ) . Women pregnant lactating . Women reproductive potential agree use effective birthcontrol method . Patients take medication know substrate CYP2B6 CYP2C19 include limited phenytoin , Phenobarbital , omeprazole , fluvoxamine efavirenz . Any clinically significant laboratory abnormality , opinion investigator , exclude patient study . An active CNS infection , demyelinate disease , degenerative neurological disease CNS disease deem progressive course study may confound interpretation study result . Any clinically significant psychiatric illness , psychological behavioral problem , opinion investigator , would interfere patient 's ability participate study . Patients suffer clinically significant active liver disease , porphyria family history severe hepatic dysfunction indicate abnormal liver function test great 3 time upper limit normal ( AST ALT ) . A history alcoholism , drug abuse , drug addiction ( within past 12 month ) . Patients would normally contraindicate YKP3089 administration . Patients participate trial involve investigational product device within 30 day screen longer require local regulation .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Seizures</keyword>
</DOC>